Specifically, C–C Motif Chemokine 22 (CCL22), a crucial immunosuppressive chemokine involved in the recruitment of regulatory T cells to the tumor microenvironment,[45] was found to be decreased in tumor tissues of the combination therapy group. The gene discussed is CCL22; the disease is neoplasm.